Should You Invest in Gilead Sciences, Inc. Today?

Before you go, we thought you'd like these...
Before you go close icon

Shares of biopharma giant GileadSciences  were up today after it announced a strong quarter, which included revenue doubling to $5 billion and earnings per share tripling from $0.43 to $1.33.

Most of the company's strength this quarter came from its hepatitis C drug Sovaldi. Sales of the drug hit $2.3 billion this quarter, which was incredible considering it was the first full quarter the drug was on the market. It also didn't hurt that sales of Stribild, Gilead's HIV pill, were up 134% year-over-year.

So should investors get in on the action? On today's Stock of the Day, Motley Fool analyst Michael Douglass says Gilead is worth watching, but it's important to be aware of the risks. One of his concerns is payer pushback, a very real threat to Gilead's hit drug Sovaldi considering that a 12-week treatment costs $84,000. Another thing Michael is keeping his eyes on is the competition--AbbVie and EnantaPharmaceuticals both have products that should hit the market soon, while Bristol-Myers Squibb and Merck both have some competing products in their pipelines as well. 


Interested in growth stocks like Gilead? Here are 3 stocks poised to be multi-baggers
The one sure way to get wealthy is to invest in a groundbreaking company that goes on to dominate a multibillion-dollar industry. Our analysts have found multi-bagger stocks time and again. And now they think they've done it again with three stock picks that they believe could generate the same type of phenomenal returns. They've revealed these picks in a new free report that you can download instantly by clicking here now.

The article Should You Invest in Gilead Sciences, Inc. Today? originally appeared on Fool.com.

Mark Reeth and Michael Douglass have no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners

12 Facts That Will Make You Smarter Than Your Friends 12 Facts That Will Make You Smarter Than Your Friends
Nature Gets Revenge On Safari Hunter Who Killed Elephants And Lions For Sport Nature Gets Revenge On Safari Hunter Who Killed Elephants And Lions For Sport
Man Is Horrified To Learn His Biological Father's Identity - But A Look In The Mirror Man Is Horrified To Learn His Biological Father's Identity - But A Look In The Mirror